These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 31578525)

  • 1. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis.
    Yoshimi A; Lin KT; Wiseman DH; Rahman MA; Pastore A; Wang B; Lee SC; Micol JB; Zhang XJ; de Botton S; Penard-Lacronique V; Stein EM; Cho H; Miles RE; Inoue D; Albrecht TR; Somervaille TCP; Batta K; Amaral F; Simeoni F; Wilks DP; Cargo C; Intlekofer AM; Levine RL; Dvinge H; Bradley RK; Wagner EJ; Krainer AR; Abdel-Wahab O
    Nature; 2019 Oct; 574(7777):273-277. PubMed ID: 31578525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Aberrant RNA splicing and development of hematological malignancies].
    Yoshimi A
    Rinsho Ketsueki; 2020; 61(6):634-642. PubMed ID: 32624537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells.
    Liang Y; Tebaldi T; Rejeski K; Joshi P; Stefani G; Taylor A; Song Y; Vasic R; Maziarz J; Balasubramanian K; Ardasheva A; Ding A; Quattrone A; Halene S
    Leukemia; 2018 Dec; 32(12):2659-2671. PubMed ID: 29858584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent SRSF2 mutations in MDS affect both splicing and NMD.
    Rahman MA; Lin KT; Bradley RK; Abdel-Wahab O; Krainer AR
    Genes Dev; 2020 Mar; 34(5-6):413-427. PubMed ID: 32001512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.
    Lee SC; Dvinge H; Kim E; Cho H; Micol JB; Chung YR; Durham BH; Yoshimi A; Kim YJ; Thomas M; Lobry C; Chen CW; Pastore A; Taylor J; Wang X; Krivtsov A; Armstrong SA; Palacino J; Buonamici S; Smith PG; Bradley RK; Abdel-Wahab O
    Nat Med; 2016 Jun; 22(6):672-8. PubMed ID: 27135740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in
    Shih AH; Meydan C; Shank K; Garrett-Bakelman FE; Ward PS; Intlekofer AM; Nazir A; Stein EM; Knapp K; Glass J; Travins J; Straley K; Gliser C; Mason CE; Yen K; Thompson CB; Melnick A; Levine RL
    Cancer Discov; 2017 May; 7(5):494-505. PubMed ID: 28193779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia.
    Hou HA; Liu CY; Kuo YY; Chou WC; Tsai CH; Lin CC; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Tien HF
    Oncotarget; 2016 Feb; 7(8):9084-101. PubMed ID: 26812887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplasia-associated mutations in serine/arginine-rich splicing factor SRSF2 lead to alternative splicing of CDC25C.
    Skrdlant L; Stark JM; Lin RJ
    BMC Mol Biol; 2016 Aug; 17(1):18. PubMed ID: 27552991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.
    Sasaki M; Knobbe CB; Munger JC; Lind EF; Brenner D; Brüstle A; Harris IS; Holmes R; Wakeham A; Haight J; You-Ten A; Li WY; Schalm S; Su SM; Virtanen C; Reifenberger G; Ohashi PS; Barber DL; Figueroa ME; Melnick A; Zúñiga-Pflücker JC; Mak TW
    Nature; 2012 Aug; 488(7413):656-9. PubMed ID: 22763442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.
    Glass JL; Hassane D; Wouters BJ; Kunimoto H; Avellino R; Garrett-Bakelman FE; Guryanova OA; Bowman R; Redlich S; Intlekofer AM; Meydan C; Qin T; Fall M; Alonso A; Guzman ML; Valk PJM; Thompson CB; Levine R; Elemento O; Delwel R; Melnick A; Figueroa ME
    Cancer Discov; 2017 Aug; 7(8):868-883. PubMed ID: 28408400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
    Wang HY; Tang K; Liang TY; Zhang WZ; Li JY; Wang W; Hu HM; Li MY; Wang HQ; He XZ; Zhu ZY; Liu YW; Zhang SZ
    J Exp Clin Cancer Res; 2016 May; 35():86. PubMed ID: 27245697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical loss of 5-hydroxymethylcytosine expression in acute myeloid leukaemia: relationship to somatic gene mutations affecting epigenetic pathways.
    Magotra M; Sakhdari A; Lee PJ; Tomaszewicz K; Dresser K; Hutchinson LM; Woda BA; Chen BJ
    Histopathology; 2016 Dec; 69(6):1055-1065. PubMed ID: 27458708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Srsf2
    Xu JJ; Chalk AM; Wall M; Langdon WY; Smeets MF; Walkley CR
    Leukemia; 2022 Dec; 36(12):2883-2893. PubMed ID: 36271153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia.
    Bamopoulos SA; Batcha AMN; Jurinovic V; Rothenberg-Thurley M; Janke H; Ksienzyk B; Philippou-Massier J; Graf A; Krebs S; Blum H; Schneider S; Konstandin N; Sauerland MC; Görlich D; Berdel WE; Woermann BJ; Bohlander SK; Canzar S; Mansmann U; Hiddemann W; Braess J; Spiekermann K; Metzeler KH; Herold T
    Leukemia; 2020 Oct; 34(10):2621-2634. PubMed ID: 32358566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and prognostic profile of SRSF2 and related spliceosome mutations in patients with acute myeloid leukemia.
    Jia W; Guo X; Wei Y; Liu J; Can C; Wang R; Yang X; Ji C; Ma D
    Mol Biol Rep; 2023 Aug; 50(8):6601-6610. PubMed ID: 37344641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.
    Kats LM; Reschke M; Taulli R; Pozdnyakova O; Burgess K; Bhargava P; Straley K; Karnik R; Meissner A; Small D; Su SM; Yen K; Zhang J; Pandolfi PP
    Cell Stem Cell; 2014 Mar; 14(3):329-41. PubMed ID: 24440599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
    Hou HA; Tien HF
    Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
    Wong JJ; Lau KA; Pinello N; Rasko JE
    Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemia.
    Choi HW; Kim HR; Baek HJ; Kook H; Cho D; Shin JH; Suh SP; Ryang DW; Shin MG
    Ann Lab Med; 2015 Jan; 35(1):118-22. PubMed ID: 25553291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution.
    Wu SJ; Kuo YY; Hou HA; Li LY; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Lin CT; Chen CY; Chou WC; Yao M; Huang SY; Ko BS; Tang JL; Tsay W; Tien HF
    Blood; 2012 Oct; 120(15):3106-11. PubMed ID: 22932795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.